ORYZON Chosen as Partner in EU's First Health IPCEI (Med4Cure Project)

The European Commission has granted approval for State aid of up to €1 billion, contributed by six Member States: Belgium, France, Hungary, Italy, Slovakia, and Spain. This financial support is part of the first Important Project of Common European Interest (IPCEI) aimed at advancing research, innovation, and the initial industrial deployment of healthcare products and innovative pharmaceutical production processes. This initiative is projected to attract an additional €5.9 billion in private sector investments.

Oryzon Genomics, S.A., a clinical-stage biopharmaceutical company specializing in epigenetics, announced its involvement as an Associated Partner in the IPCEI Med4Cure macro-project, which encompasses 14 scientific projects. Med4Cure involves 13 companies as Direct Partners and 11 as Associated Partners. Oryzon's specific project, named VANDAM, focuses on validating experimental epigenetic drugs using a personalized medicine approach tailored for rare and orphan diseases.

Spain's participation in the IPCEI Med4Cure is included in the country's Recovery and Resilience Plan, allowing it to partly fund these projects through the Recovery and Resilience Facility. Detailed information on the amount of aid each participant receives will be disclosed publicly after resolving confidentiality issues with Member States and third parties.

Dr. Carlos Buesa, CEO of Oryzon, expressed gratitude to EU officials and the Spanish governmental agency CDTI for their support. Dr. Buesa highlighted the significance of this multinational EU project in providing European citizens and future generations with innovative precision medicines for rare diseases. The company promised to release more details on their project activities, budget, and the State-Aid received once confidentiality matters are addressed.

Oryzon Genomics, founded in 2000 in Barcelona, Spain, stands as a European leader in epigenetics with a focus on personalized medicine for central nervous system (CNS) disorders and oncology. The company operates from Barcelona, Boston, and San Diego, consisting of highly qualified professionals from the pharmaceutical industry. Its advanced clinical portfolio includes two LSD1 inhibitors: vafidemstat for CNS disorders and iadademstat for oncology, currently in Phase II clinical trials. Additionally, Oryzon is developing other pipeline assets targeting epigenetic markers, such as HDAC-6, with ORY-4001 designated as a clinical candidate for treating neurological disorders like Charcot-Marie-Tooth (CMT) disease and amyotrophic lateral sclerosis (ALS). Oryzon also has a robust platform for biomarker identification and target validation for various malignant and neurological diseases.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!